Resources

This document presents new research results from PATH's HPV Vaccines: Evidence for Impact project in Peru. PATH is working with ministries of health and other country partners to develop strategies for introducing vaccines against human papillomavirus (HPV), the primary cause of cervical cancer.

This document presents new research results from PATH's HPV Vaccines: Evidence for Impact project in Uganda. PATH is working with ministries of health and other country partners to develop strategies for introducing vaccines against human papillomavirus (HPV), the primary cause of cervical cancer.

This document presents formative research results from PATH's HPV Vaccines: Evidence for Impact project in Vietnam. PATH is working with ministries of health and other country partners to develop strategies for introducing vaccines against human papillomavirus (HPV), the primary cause of cervical cancer.

This document presents formative research results from PATH's HPV Vaccines: Evidence for Impact project in India. PATH is working with ministries of health and other country partners to develop strategies for introducing vaccines against human papillomavirus (HPV), the primary cause of cervical cancer.

The MDR/XDR-TB Assessment and Monitoring Tool was designed to help national tuberculosis program staff, consultants, and donors conduct a baseline assessment for use in preparing a plan or funding application, monitoring progress, or identifying needs for technical assistance. It addresses two key questions: are there high-priority gaps in the DOTS program that must be corrected to prevent the development of cases of multidrug-resistant/extensively drug-resistant (MDR/XDR-TB), and what high-priority areas should be addressed to improve diagnosis and treatment of MDR/XDR-TB? The tool is available in English, Russian, and Spanish as a Microsoft Word file (for users who wish to modify it) and as an Adobe PDF file (recommended for printing). This 2009 tool informed the 2012 MDR-TB Planning Toolkit, which can be found here.